Maze Therapeutics, Inc.
MAZE
$27.18
-$0.49-1.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 56.53% | 58.61% | 39.67% | 13.14% | 41.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.70% | 31.50% | 28.03% | 23.33% | 43.34% |
| Operating Income | -31.70% | 24.99% | -28.03% | -36.06% | -126.14% |
| Income Before Tax | -32.80% | 26.16% | -15.79% | -20.20% | -123.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.80% | 26.16% | -16.87% | -21.55% | -124.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.80% | 26.16% | -16.87% | -21.55% | -124.22% |
| EBIT | -31.70% | 24.99% | -28.03% | -36.06% | -126.14% |
| EBITDA | -32.99% | 24.79% | -29.42% | -38.19% | -125.51% |
| EPS Basic | 1.42% | 60.78% | 67.91% | 93.59% | -105.06% |
| Normalized Basic EPS | 1.41% | 60.79% | 94.42% | 92.91% | -101.31% |
| EPS Diluted | 1.30% | 60.78% | 71.98% | 93.56% | -111.41% |
| Normalized Diluted EPS | 1.41% | 60.79% | 94.42% | 92.91% | -103.02% |
| Average Basic Shares Outstanding | 34.70% | 88.26% | 2,095.73% | 1,794.93% | 1,725.04% |
| Average Diluted Shares Outstanding | 34.70% | 88.26% | 2,095.73% | 1,794.93% | 693.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |